FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933348020> ?p ?o ?g. }

• W2933348020 endingPage "1277" @default.
• W2933348020 startingPage "1262" @default.
• W2933348020 abstract "Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. Around half of patients with HCC will receive systemic therapies during their life span. The pivotal positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative studies with drugs leading to marginal antitumoral efficacy, toxicity, or trials with a lack of enrichment strategies. This trend has changed over the last 2 years with several compounds, such as lenvatinib (in first-line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line), showing clinical benefit. These successes came at a cost of increasing the complexity of decision-making, and ultimately, impacting the design of future clinical trials. Nowadays, life expectancy with single active agents has surpassed the threshold of 1 year and sequential strategies have provided encouraging outcomes. Overall survival (OS) remains the main endpoint in phase III investigations, but as in other solid tumours, there is a clear need to define surrogate endpoints that both reliably recapitulate survival benefits and can be assessed before additional efficacious drugs are administered. A thorough analysis of 21 phase III trials published in advanced HCC demonstrated a moderate correlation between progression-free survival (PFS) or time to progression (TTP) and OS (R = 0.84 and R = 0.83, respectively). Nonetheless, the significant differences in PFS identified in 7 phase III studies only correlated with differences in OS in 3 cases. In these cases, the hazard ratio (HR) for PFS was ≤0.6. Thus, this threshold is herein proposed as a potential surrogate endpoint of OS in advanced HCC. Conversely, PFS with an HR between 0.6-0.7, despite significance, was not associated with better survival, and thus these magnitudes are considered uncertain surrogates. In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival." @default.
• W2933348020 created "2019-04-11" @default.
• W2933348020 creator A5024715423 @default.
• W2933348020 creator A5052975894 @default.
• W2933348020 creator A5059651582 @default.
• W2933348020 date "2019-06-01" @default.
• W2933348020 modified "2023-10-08" @default.
• W2933348020 title "Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival" @default.
• W2933348020 cites W1007890594 @default.
• W2933348020 cites W1537544985 @default.
• W2933348020 cites W1570249624 @default.
• W2933348020 cites W1584669207 @default.
• W2933348020 cites W1739036892 @default.
• W2933348020 cites W1828082159 @default.
• W2933348020 cites W1873011119 @default.
• W2933348020 cites W1964051982 @default.
• W2933348020 cites W1971159432 @default.
• W2933348020 cites W1971837077 @default.
• W2933348020 cites W1972833072 @default.
• W2933348020 cites W1974342793 @default.
• W2933348020 cites W1974744928 @default.
• W2933348020 cites W1975154077 @default.
• W2933348020 cites W1981859071 @default.
• W2933348020 cites W1994193851 @default.
• W2933348020 cites W1998483833 @default.
• W2933348020 cites W2000390268 @default.
• W2933348020 cites W2000681830 @default.
• W2933348020 cites W2012439317 @default.
• W2933348020 cites W2019607817 @default.
• W2933348020 cites W2021135937 @default.
• W2933348020 cites W2026191784 @default.
• W2933348020 cites W2036922484 @default.
• W2933348020 cites W2046000826 @default.
• W2933348020 cites W2050249255 @default.
• W2933348020 cites W2051684210 @default.
• W2933348020 cites W2066597933 @default.
• W2933348020 cites W2077813812 @default.
• W2933348020 cites W2079586464 @default.
• W2933348020 cites W2083748784 @default.
• W2933348020 cites W2086117966 @default.
• W2933348020 cites W2086804632 @default.
• W2933348020 cites W2095943598 @default.
• W2933348020 cites W2100158834 @default.
• W2933348020 cites W2100297634 @default.
• W2933348020 cites W2101031676 @default.
• W2933348020 cites W2101459399 @default.
• W2933348020 cites W2102942095 @default.
• W2933348020 cites W2105677105 @default.
• W2933348020 cites W2108881270 @default.
• W2933348020 cites W2109746877 @default.
• W2933348020 cites W2111070218 @default.
• W2933348020 cites W2113057788 @default.
• W2933348020 cites W2113788015 @default.
• W2933348020 cites W2115140387 @default.
• W2933348020 cites W2119242310 @default.
• W2933348020 cites W2120967735 @default.
• W2933348020 cites W2123532766 @default.
• W2933348020 cites W2123546830 @default.
• W2933348020 cites W2126251787 @default.
• W2933348020 cites W2127645603 @default.
• W2933348020 cites W2128965737 @default.
• W2933348020 cites W2135403187 @default.
• W2933348020 cites W2135753750 @default.
• W2933348020 cites W2136415416 @default.
• W2933348020 cites W2140409228 @default.
• W2933348020 cites W2140587309 @default.
• W2933348020 cites W2142020092 @default.
• W2933348020 cites W2147172608 @default.
• W2933348020 cites W2153867442 @default.
• W2933348020 cites W2153935627 @default.
• W2933348020 cites W2155311724 @default.
• W2933348020 cites W2155514044 @default.
• W2933348020 cites W2156778867 @default.
• W2933348020 cites W2157535532 @default.
• W2933348020 cites W2157769714 @default.
• W2933348020 cites W2158207366 @default.
• W2933348020 cites W2158378236 @default.
• W2933348020 cites W2162242700 @default.
• W2933348020 cites W2163403599 @default.
• W2933348020 cites W2163557371 @default.
• W2933348020 cites W2165901246 @default.
• W2933348020 cites W2277004004 @default.
• W2933348020 cites W2291203170 @default.
• W2933348020 cites W2293085462 @default.
• W2933348020 cites W2296049142 @default.
• W2933348020 cites W2315422051 @default.
• W2933348020 cites W2343159740 @default.
• W2933348020 cites W2397053700 @default.
• W2933348020 cites W2412696100 @default.
• W2933348020 cites W2470906679 @default.
• W2933348020 cites W2495512985 @default.
• W2933348020 cites W2560499218 @default.
• W2933348020 cites W2581205085 @default.
• W2933348020 cites W2592144107 @default.
• W2933348020 cites W2592294623 @default.
• W2933348020 cites W2606367731 @default.
• W2933348020 cites W2613362156 @default.
• W2933348020 cites W2626033245 @default.

• next